Treating T-cell rejection after kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 2 years old.
- You have received a kidney or kidney-pancreas transplant.
- A biopsy shows you have a type of rejection called T-cell mediated rejection (TCMR).
- You do not have other types of rejection (like antibody-mediated rejection) or a mix of rejections.
- You do not have an active cancer or infection that would make it risky to take stronger anti-rejection medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This trial tests a new two-step treatment for a type of long-term kidney rejection (chronic active antibody-mediated rejection) in transplant recipients. First, you receive an infusion of CD38 antibodies to clear harmful cells, then a months-long course of azathioprine pills to maintain the benefit and protect your kidney.
Hear when a new Rejection; Transplant, Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.